Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Subscribe to Free Drug Patent Expiration Updates

Also available in a Drug Patent Expiration NewsletterRSS feed and on Drug Patent Expirations on TwitterTwitter

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: KAPVAY

« Back to Dashboard
Kapvay is a drug marketed by Concordia Pharms Inc and is included in one NDA. It is available from one supplier.

The generic ingredient in KAPVAY is clonidine hydrochloride. There are twenty-one drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the clonidine hydrochloride profile page.

Summary for Tradename: KAPVAY

Suppliers / Packagers: see list3

Pharmacology for Tradename: KAPVAY

Clinical Trials for: KAPVAY

Efficacy & Safety of KAPVAY™ Extended-Release in Children & Adolescents With Attention Deficit Hyperactivity Disorder
Status: Completed Condition: Attention Deficit Hyperactivity Disorder

Phase 1 PK, Bioavailability, Safety Study of Clonidine MBT w Catapres in Healthy Volunteers
Status: Recruiting Condition: Healthy

Effect of Intrathecal Clonidine in Hypertensive Subjects With Poorly Controlled Blood Pressure
Status: Completed Condition: Hypertension

Bioequivalence of Two Transdermal Clonidine Administrations in Healthy Volunteers
Status: Completed Condition: Healthy

Intrathecal Clonidine in Cesarean Section May Lead to Worse Blood Gas Results in the Newborns
Status: Completed Condition: Pregnancy

Epidural Clonidine for Lumbosacral Radiculopathy
Status: Terminated Condition: Lumbar and Other Intervertebral Disc Disorders With Radiculopathy

Ropivacaine With Clonidine For Pediatric Rectus Sheath Blocks- The Magic Combination
Status: Not yet recruiting Condition: Postoperative Pain

The Effect of Clonidine-enhanced Sedation on Delirium in Ventilated Critically Ill Patients
Status: Not yet recruiting Condition: Delirium

Comparison of Epidural Fentanyl and Clonidine for Breakthrough Pain
Status: Recruiting Condition: Labor Pain

Safety of Clonidine in Infants With Hypoxic Ischemic Encephalopathy During Therapeutic Hypothermia
Status: Not yet recruiting Condition: Encephalopathy, Hypoxic-Ischemic

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Concordia Pharms Inc
clonidine hydrochloride
TABLET, EXTENDED RELEASE;ORAL022331-003Sep 28, 2010RXYes<disabled><disabled>
Concordia Pharms Inc
clonidine hydrochloride
TABLET, EXTENDED RELEASE;ORAL022331-004Sep 28, 2010DISCNNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: KAPVAY

Drugname Dosage Strength RLD Submissiondate
clonidine hydrochlorideExtended-release Tablets0.1 mg and 0.2 mgKapvay3/4/2011
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn